Praxis Precision Medicines, Inc. Announces Pricing of $525 Million Public Offering

Core Viewpoint - Praxis Precision Medicines, Inc. has announced a public offering of 3,025,480 shares of common stock priced at $157.00 per share, along with pre-funded warrants for an additional 318,470 shares, aiming to raise approximately $525 million in gross proceeds before expenses [1] Group 1: Offering Details - The offering includes 3,025,480 shares of common stock priced at $157.00 each and pre-funded warrants to purchase up to 318,470 shares at a price of $156.9999 per warrant [1] - The gross proceeds from the offering are expected to be around $525 million, excluding underwriting discounts and commissions [1] - Praxis has granted underwriters a 30-day option to purchase up to 501,592 additional shares at the public offering price [1] Group 2: Underwriters - TD Cowen, Piper Sandler, Guggenheim Securities, and Truist Securities are acting as joint book-running managers for the offering [2] - Oppenheimer & Co. and H.C. Wainwright & Co. are serving as lead managers for the offering [2] Group 3: Regulatory Information - The offering is made under a shelf registration statement on Form S-3ASR, which became effective upon filing with the SEC on December 23, 2024 [3] - A preliminary prospectus supplement was filed with the SEC on October 16, 2025, with the final prospectus supplement to be filed subsequently [3]